In addition to these typical GRN loss-of-function mutations, a large number of silent and missense mutations in GRN have also been reported, although their role in neurodegenerative disease pathogenesis has remained less clear [ 38].
Besides pathogenic ATM mutations, a large number of ATM variants (common polymorphisms and unclassified variants) have been described, which were found in cancer patients as well as in the general population.
When 100% of patients had wild type EGFR, the model suggested that there is no difference in PFS with TKIs compared with no active treatment (HR, 0.95; 95% CI, 0.65-1.38; P =.78), whereas when 100% of patients had EGFR mutations, a large benefit of TKIs was indicated (HR, 0.12; 95% CI, 0.02-0.66; P =.015; Figure 5).
In a previous study, as many as 44% of vulvar carcinomas were shown to have TP53 mutations; a large proportion of these also over-expressed p53 protein due to limited degradation as a consequence of structural alterations of the protein [ 33].
While other genes, such as PS1 and tau have been manipulated alone or in combination with APP mutations, a large portion of the current literature describing the AD-like neurodegenerative phenotypes in animal models has been based on animal models expressing high levels of mutant APP.
Of particular interest were cases 7, 8, and 10, in which T790M mutations were not detected by high-sensitivity conventional PCR-based methods, such as peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp [ 16], or Cycleave real-time PCR [ 15].> In addition to T790M mutations, a large number of activating mutations were identified outside of EGFR.
In fact, cancerous cells have, due to mutations, a larger number of gene copies, and thus predictions for tumor's invaded systems are not the same as for healthy ones.
However, despite the apparent simplicity of the mutation, a large number of cellular pathways, and molecular targets, have been implicated in the disease pathology [3].
A pathogenic mutation was defined to be a variant that was predicted to result in a stop codon, a frameshift mutation, a large insertion or deletion, or a missense mutation previously reported in the scientific literature to be pathogenic.
For a given founder mutation a large number of carriers are available, so that focused scientific studies of penetrance, expression, and genetic and environmental modifiers of risk can be performed.
Common and rare FRI mutations along with rare FLC mutations explain a large fraction of flowering-time variation in A. thaliana.
